Clinical Trials on Encephalitis, Japanese in Australia

Total 31 results

Sanofi

Completed

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

Japanese Encephalitis

Australia
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Sanofi

Completed

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Japanese Encephalitis | Encephalitis

Australia
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Sanofi

Completed

Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)

Japanese Encephalitis | Yellow Fever

Australia
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Sanofi

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Japanese Encephalitis

Australia, United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

Japanese Encephalitis | Rabies

Austria, Germany, Switzerland
Sanofi

Completed

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Japanese Encephalitis | Encephalitis

United States, Australia
Medical University of Vienna

Completed

6-year Antibody Check After Third Vaccination Against Japanese Encephalitis

Post Other Specified Vaccination Encephalitis

Austria
Medical University of Vienna
Austrian Science Fund (FWF)

Completed

Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

Tick Borne Encephalitis

Austria
Elisabethinen Hospital
Baxter Healthcare Corporation; ASOKLIF

Unknown

Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine (immunisation)

Tick Borne Encephalitis

Austria, Czech Republic
Medical University of Vienna

Unknown

Application of a TBE-Vaccine in Obese Persons

Tick Borne Encephalitis

Austria
Pfizer

Completed

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Encephalitis, Tick-borne

Austria
Medical University of Vienna

Completed

Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination

Tick-borne Encephalitis

Austria
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Encephalitis, Tick-Borne

Germany, Austria, Poland
Medical University of Vienna

Completed

TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Vaccine Responsiveness in Allergy | Vaccine Responsiveness During Allergy De-sensitization Treatment

Austria
Pfizer

Completed

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

Encephalitis, Tick-Borne

Austria, Germany, Poland
Pfizer

Completed

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Encephalitis, Tick-borne

Austria
Pfizer

Completed

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Encephalitis, Tick-Borne

Austria, Czechia
Pfizer

Completed

Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Tick-borne Encephalitis

Austria, Germany, Poland
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Encephalitis, Tick-borne

Austria, Germany
Pfizer

Completed

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

Tick-borne Encephalitis

Austria, Germany
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

NMDAR Autoimmune Encephalitis | LGI1 Autoimmune Encephalitis

United States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, France, Denmark, Ghana
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
ICUREsearch

Completed

EURopean Study on Encephalitis in Intensive CAre (EURECA)

Encephalitis

France, Spain, Italy, Netherlands, Austria, India
Infectopharm Arzneimittel GmbH
INPADS GmbH; Dr. Oestreich + Partner GmbH

Recruiting

Fosfomycin i.v. for Treatment of Severely Infected Patients (FORTRESS)

Respiratory Tract Infections | Sepsis | Encephalitis | Bacterial Infections | Intraabdominal Infections | Bacteremia | Skin Diseases, Bacterial | Pneumonia, Bacterial | Urinary Tract Infections | Meningitis, Bacterial | Central Nervous System Bacterial Infections | Soft Tissue Infections | Endocarditis, Bacterial | Bone Diseases, Infectious and other conditions

Germany, Austria, Greece, Italy, United Kingdom

3

Subscribe